TMEM219 and breast carcinoma: Other clinical subgroups of breast cancer patients included “breast_carcinoma_surgical_procedure_name-Modified Radical Mastectomy” (IGFBP-3, FDR = 1.26∙10−1 (HR = 0.44), Figure 10A), “lab_proc_her2_neu_immunohistochemistry_receptor_status-Equivocal” (TMEM219, FDR = 3.27∙10−1 (HR = 3.29)).